iBio secures $26mln private placement for antibody therapy development.
ByAinvest
Monday, Jan 12, 2026 5:31 pm ET1min read
IBIO--
IBIO--
iBio has entered into a $26 million private placement financing led by Frazier Life Sciences and other existing investors. The proceeds will be used to advance preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin and activin A bispecific. The offering is expected to close on January 13, 2026, subject to customary closing conditions.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet